Glatiramer Acetate Articles
Teva gets favorable UK Copaxone patent ruling
12 July 2012
Recent Gilenya growth appears to be coming from initial trial among late adopters not expanded use among existing prescribers
30 November 2011
Court rejects Teva's motion to prevent Watson launch of generic Seasonique; nabumetone OKed; Mylan Copaxone judgment
20 June 2011
US Supreme Court agrees to hear generic drug labelling case; Teva files to stop generic Copaxone
13 December 2010
New Zealand’s PHARMAC enters deal with InterPharma for seven cancer drugs and with Bayer over Xarelto, Avelox and Copaxone
10 November 2010
Mylan gets US approval for copy version of Astellas’ immunosuppressant Prograf; Teva files complaint over Copaxone patents
22 September 2010
Asthma drug albuterol may also benefit patients with multiple sclerosis
15 September 2010
US FDA rejects Teva’s second try to block generic Copaxone; Shire sues Actavis over Intuniv
14 May 2010
Teva returns to profit, as 4th quarter 2009 sales leap 33%
16 February 2010
Does the MS market need another Interferon? US neurologists provide insight on the launch of Novartis’ Extavia
12 January 2010
Teva sets goals of $31 billion revenues and non-GAAP net income of $6.8 billion by 2015
8 January 2010
UK Department of Health’s “money back” deal for MS drugs questioned; failing people with the disease
3 December 2009
Teva files suit against Momenta/Sandoz over Copaxone, OK for generic Prevacid in USA for Teva and Mylan
11 November 2009
Teva's 1st-qtr profit more than triples
6 May 2009
FDA declines to review Teva's Citizen Petition
27 March 2009
Teva gets expanded US indication for Copaxone
9 March 2009
Teva profit down 67% on Barr merger costs
23 February 2009
Teva's Copaxone cleared in EU as preventative treatment
9 February 2009
Teva sales up 20% but Wall Street is cautious
17 November 2008
Teva presents results from the PreCISe trial
29 September 2008
Teva files patent suit against Novartis over Copaxone
8 September 2008
Teva's 2nd-qtr 2008 profit up 5% to $539M
18 August 2008
Teva targets Japanese market, says CEO
4 August 2008
Teva
14 July 2008
Teva reveals Copaxone sales
5 May 2008
Sanofi-Aventis
5 May 2008
Positive results from Teva's PreCISe Copaxone study
28 April 2008
New data on Teva's Copaxone positive
21 April 2008
Sanofi stops marketing Teva's Copaxone in USA
7 April 2008
Teva's 4th-qtr income climbs 24% US sales
18 February 2008
Teva's 3rd-qtr income falls 13%
5 November 2007
500mcg Betaferon fails to show result in RRMS
5 November 2007
Copaxone shows long-term benefits in MS
22 October 2007
Merck KGaA
15 October 2007
Teva's 2nd-qtr 2007 net sales rise 10% to $2.39B
20 August 2007
Copaxone storage requirements relaxed
11 June 2007
Teva's 1st-qtr 2007 net sales rise 24% to $2.08B
14 May 2007
Teva's 4th-qtr profits up 42%, but EPS falls short
19 February 2007
Generics, including Plavix, and govt cost-cutting hit Sanofi-Aventis' 3rd-qtr results
6 November 2006
Superior adherence with BI's Avonex
9 October 2006
MS patients on Teva's Copaxone miss less working days
18 September 2006
Teva's net rockets 124% in 2nd-qtr 2006
14 August 2006
Teva details Copaxone business
7 August 2006
Teva and Eisai halt US collaboration on rasagiline
17 July 2006
Teva's Copaxone: "less relapses than Avonex"
12 June 2006
Teva sees 1st-qtr loss of $1.2B, due to IVAX buy
22 May 2006
Teva presents Copaxone sales data
15 May 2006
High-dose Copaxone effective in RRMS trial
17 April 2006
Serono 4th qtr shows profit but disappoints
13 February 2006
New Zealand funds Teva's MS drug Copaxone
5 December 2005
Teva's 2nd-qtr lifted by non-US business
8 August 2005
Strong 2nd qtr for Sanofi-Aventis
25 July 2005
Schering AG completes enrollment in Betaferon trial
25 July 2005
Positive comparative data on Copaxone
20 June 2005
Teva 1st-qtr net profit leaps 26%
16 May 2005
Teva's 4th-qtr income soars 40%
21 February 2005
Sanofi-Aventis 2004 sales rise 10%
31 January 2005
Serono completes enrollment in Rebif vs Copaxone trial
10 January 2005
Copaxone 3rd-qtr sales rise 34% to $242M
1 November 2004
Sicor acquisition lifts Teva results
9 August 2004
MS risk-sharing in UK: "a great deal to be done"
21 June 2004
Teva pays $5M for Active Bio's MS drug
21 June 2004
Glatiramer for MS may provide no benefit
7 June 2004
Teva reports record annual sales of $3.3B
1 March 2004
Teva stays ahead of the pack with $3.4 billion Sicor acquisition
10 November 2003
Aventis/Teva's Copaxone fully available in France
6 October 2003
MS postcode Rxing "still exists in UK"
12 May 2003
Teva sales grow 39%, EPS up 56% in 1st qtr
12 May 2003
MS Rx costs are high but fall over time: study
17 March 2003
Earnings up at Teva on strong generic sales
24 February 2003
Study questions long-term IFN use in MS
24 February 2003
Teva's net income leaps 43% in 2nd qtr
12 August 2002
Pfizer's muscle to support Rebif in USA
15 July 2002
Ready-to-use Copaxone launched in Canada
27 May 2002
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Italy's pharma market slump set to continue, warns GlobalData
